Celyad Oncology SA · EURONEXT:CYAD

Celyad Oncology SA — Fact Sheet (May 2022)

2 slides from Celyad Oncology SA's fact sheet, May 4, 2022

  1. Slide 1: Allogeneic vs Autologous CAR T: Allogeneic CAR T

    Allogeneic vs Autologous CAR T Allogeneic CAR T • Can be manufactured at larger scale • Potential risk for Graft- Off-the-Shelf Approach • Ready when the patient needs versus-Host & Host- (Treatment ready to use when needed) treatment versus-Graft • Off-the-Shelf therapy allows for more complication

  2. Slide 2: Allogeneic vs Autologous CAR T: Autologous CAR T

    Allogeneic vs Autologous CAR T Autologous CAR T Step 2 Step 1 Cells engineered • Tailor-made for an individual’s • Not appropriate for large Cells harvested from cancer batch production due to healthy donor’s blood • Minimal risk of rejection of manufacturing capacity cells or alloreactivity since c

Celyad Oncology — Fact Sheet (May 2022) on 6ix